喘患者血清中介质素-33,可溶性ST2和IgE水平:一个病例对照研究
Himadri Singh1, Alkesh Khurana2, Ashok Kumar1
1Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.
概括
喘患者表现出更高的干白素-33 (IL-33) 和免疫球蛋白E (IgE) 水平,以及更低的可溶性ST2 (sST2) 水平. IL-33与IgE和埃索诺菲尔相关,这表明喘中的潜在生物标志物作用.
科学领域:
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
- 生物化学 生化学
背景情况:
- 干细胞蛋白在喘病理生理学中至关重要.
- 介素-33 (IL-33) 是一种细胞因子,与喘有关.
- IL-33与其受体相互作用,抑制瘤发生性2 (ST2).
研究的目的:
- 评估喘患者与健康对照者的IL-33,sST2和IgE血清水平.
- 调查这些标记物与FEV1%和绝对乙酸细胞计数 (AEC) 的相关性.
主要方法:
- 分析了来自100名喘患者和57名健康对照者的血清样本.
- 测量了IgE,IL-33和sST2的水平.
- 使用GraphPad Prism 8.进行统计分析.
主要成果:
- 与对照组相比,喘患者的IL-33和IgE水平显著提高.
- 在喘患者中,sST2水平显著降低.
- 在过敏性喘患者中,IL-33水平与IgE和AEC有显著的相关性.
- 在不受控制的喘中观察到FEV1%的降低.
结论:
- 升高的IL-33和IgE,随着sST2的降低,是喘的特征.
- IL-33和sST2显示出作为喘等过敏性疾病的炎症生物标志物的潜力.
相关概念视频
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
346
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
346
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Asthma-I: Introduction
2.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
299
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
299
Antiasthma Drugs: Leukotriene Modifiers
357
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
357


